Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants
Immunity · 2024-04 · 57 (4) · 912-925.e4
DOI: 10.1016/j.immuni.2024.02.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, 2024-04. Verfasst von Timothy S Johnston und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; Institute for Immunology and Immune Health…. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 103-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust, NIAID NIH HHS, NIH HHS.
Abstract (Originalsprache)
The spike glycoprotein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) continues to accumulate substitutions, leading to breakthrough infections of vaccinated individuals. It remains unclear if exposures to antigenically distant SARS-CoV-2 variants can overcome memory B cell biases established by initial SARS-CoV-2 encounters. We determined the specificity and functionality of antibody and B cell responses following exposure to BA.5 and XBB variants in individuals who received ancestral SARS-CoV-2 mRNA vaccines. BA.5 exposures elicited antibody responses that targeted epitopes conserved between the BA.5 and ancestral spike. XBB exposures also elicited antibody responses that primarily targeted epitopes conserved between the XBB.1.5 and ancestral spike. However, unlike BA.5, a single XBB exposure elicited low frequencies of XBB.1.5-specific antibodies and B cells in some individuals. Pre-existing cross-reactive B cells and antibodies were correlated with stronger overall responses to XBB but weaker XBB-specific responses, suggesting that baseline immunity influences the activation of variant-specific SARS-CoV-2 responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; Institute for Immunology and Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia…
- Department of Microbiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
- Institute for Immunology and Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Pe…
- Institute for Immunology and Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases),…
- Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA.
Förderung
- Wellcome Trust
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
- U.S. Department of Health and Human Services
- Burroughs Wellcome Fund
- Parker Institute for Cancer Immunotherapy
- Boehringer Ingelheim Fonds
Zitieren
APA
Johnston, T. S., Li, S. H., Painter, M. M., Atkinson, R. K., Douek, N. R., Reeg, D. B., Douek, D. C., Wherry, E. J., & Hensley, S. E. (2024). Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants. Immunity, 57(4), 912-925.e4. https://doi.org/10.1016/j.immuni.2024.02.017
Vancouver
Johnston TS, Li SH, Painter MM, Atkinson RK, Douek NR, Reeg DB, et al. Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants. Immunity. 2024;57(4):912-925.e4. doi:10.1016/j.immuni.2024.02.017
BibTeX
@article{Johnston2024,
author = {Johnston, Timothy S and Li, Shuk Hang and Painter, Mark M and Atkinson, Reilly K and Douek, Naomi R and Reeg, David B and Douek, Daniel C and Wherry, E John and Hensley, Scott E},
title = {Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants},
journal = {Immunity},
year = {2024},
volume = {57},
number = {4},
pages = {912--925.e4},
doi = {10.1016/j.immuni.2024.02.017}
}
EUVIMED